TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36897251
Drug: CD19 CAR
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19 CAR T-cell therapy combined with autologous CD19+ feeding T cells (FTCs) and tyrosine kinase inhibitor (TKI) as consolidation therapy.
Study: 36897251
Drug: CD19 CAR
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19 CAR T-cell therapy combined with autologous CD19+ feeding T cells (FTCs) and TKI as consolidation therapy.
Study: 36897310
Drug: Endometriosis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometriosis treatment
Study: 36897310
Drug: Migraine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine treatment
Study: 36897592
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of discount and default options
Study: 36897592
Drug: Combination condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination condition
Study: 36897863
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy (RAT)
Study: 38319937
Drug: Community-wide mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide mass drug administration (cMDA) for soil-transmitted helminths (STH)
Study: 36898391
Drug: Vaccinated patients
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated patients (booster and two doses)
Study: 36898400
Drug: Intramuscular Ad5-nCoV
Normalized name: Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Ad5-nCoV
Study: 36898933
Drug: Chimeric antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor T-cell therapy
Study: 36898949
Drug: Using Peer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using Peer Support to Aid in Prevention and Treatment in Prediabetes
Study: 36899125
Drug: MenACYW-TT booster
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACYW-TT booster vaccination with co-administration of MenB vaccine
Study: 36899351
Drug: Structured educational
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured educational intervention involving lower limb physical exercise and daily ambulation guidelines
Study: 36899351
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment in primary care (cleansing, debridement, healing in a moist environment, multilayer compression therapy)
Study: 36899369
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg once daily
Study: 36899430
Drug: Silymarin 700mg
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 700mg + 8mg vitamin E + 50mg phosphatidylcholine daily
Study: 36899430
Drug: Maltodextrin 700mg
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin 700mg + 8mg vitamin E + 50mg phosphatidylcholine daily (Control)
Study: 36900279
Drug: Segmental Abutting
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Segmental Abutting Esophagus-Sparing (SAES) radiotherapy (45 Gy in 3 Gy daily fractions over 3 weeks)
Study: 36900554
Drug: Ginger extract
Normalized name: ginger extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger extract (100 mL, 0.2 g/100 mL)
Study: 36900554
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (200 mL)
Study: 36900811
Drug: Continued physical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued physical activity on prescription at a healthcare center (HCC)
Study: 36900872
Drug: SUNFRAIL questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUNFRAIL questionnaire administered by seven centers.
Study: 36902139
Drug: BCL-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCL-2 inhibitors (specific drugs not detailed)
Study: 36902139
Drug: PD-1/PD-L1 pathway
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 pathway inhibitors (specific drugs not detailed)
Study: 36902217
Drug: MRD-directed therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRD-directed therapy, specific drugs and dosages not mentioned, duration not mentioned
Study: 36902217
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without MRD-directed therapy, specific drugs and dosages not mentioned, duration not mentioned
Study: 36902861
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (closed reduction and dorsal casting for 5 weeks) for displaced DRFs
Study: 36902861
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (closed reduction and dorsal casting for 5 weeks) for minimally or non-displaced DRFs
Study: 36902861
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (closed reduction and dorsal casting for 5 weeks) for both groups
Study: 36904251
Drug: Walnut supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut supplementation (15% of daily energy)
Study: 36905161
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation (E-Stim) on both gastrocnemius muscles for 1 hour daily for 4 weeks
Study: 36905498
Drug: TV-46000 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV-46000 (subcutaneous LAI antipsychotic agent)
Study: 36905771
Drug: Fulvestrant (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant (500 mg on days 0, 14 and 28, then every 28 ± 3 days, n = 77)
Study: 36905771
Drug: Exemestane (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25 mg/day, n = 67)
Study: 36905980
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + ECIG retraining
Study: 36905980
Drug: CC only
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC only retraining
Study: 36906081
Drug: Polysaccharide hemostatic
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide hemostatic powder (PHP) with diluted epinephrine injection and powder application as spray
Study: 36906081
Drug: Conventional endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional endoscopic treatment (electrical coagulation or hemoclipping after diluted epinephrine injection)
Study: 36906664
Drug: CD46-targeted alpha
Normalized name: alpha-Tocopherolquinone
DrugBank: Tocopherylquinone (DB14094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD46-targeted alpha therapy based on YS5
Study: 36906664
Drug: Microtubule inhibitor-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microtubule inhibitor-based antibody drug conjugate
Study: 36906875
Drug: Intravenous CYT107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CYT107 (10 µg/kg)
Study: 36906875
Drug: Intravenous CYT107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CYT107
Study: 36906875
Drug: Intramuscular CYT107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular CYT107 (previous study)
Study: 36907945
Drug: M-DEPTH depression
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-DEPTH depression care model (including antidepressants and individual Problem Solving Therapy)
Study: 36907947
Drug: Alofanib (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alofanib (350 mg/m2, administered daily intravenously 5 days on, 2 days off)
Study: 36907997
Drug: Antenatal azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antenatal azithromycin (500 mg oral tablets)
Study: 36908150
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg pitavastatin
Study: 36908150
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg pitavastatin/10 mg ezetimibe (K-924 LD)
Study: 36908150
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg pitavastatin/10 mg ezetimibe (K-924 HD)
Study: 36908150
Drug: Pitavastatin/ezetimibe fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin/ezetimibe fixed-dose combination
Study: 36908150
Drug: Pitavastatin/ezetimibe fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin/ezetimibe fixed-dose combination and pitavastatin monotherapy
Study: 36908314
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg per day
Study: 36908609
Drug: High-dose corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroids treatment
Study: 36908619
Drug: ApTOLL (Toll-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApTOLL (Toll-like receptor 4 antagonist) administered together with endovascular treatment (EVT)
Study: 36908619
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered together with endovascular treatment (EVT)
Study: 36908766
Drug: Pain, depression,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain, depression, and anxiety medications
Study: 36910457
Drug: Urinary L-type
Normalized name: hydroxypropyl cellulose (type L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary L-type fatty acid-binding protein (L-FABP) measured within 48 hours of admission
Study: 36910457
Drug: L-FABP point
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-FABP point of care (POC) test
Study: 36910501
Drug: Active acupuncture
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active acupuncture (three times weekly for 14 weeks) added to donepezil treatment (5 mg per day for 28 weeks)
Study: 36910501
Drug: Non-penetrating sham
Normalized name: Clearskin Pore Penetrating Black Mineral Mask
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-penetrating sham acupuncture (three times weekly for 14 weeks) added to donepezil treatment (5 mg per day for 28 weeks)
Study: 36910537
Drug: Cardiac shock-wave
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac shock-wave therapy (CSWT)
Study: 36910668
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy based on molecular profiles
Study: 36910693
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
Normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) once daily for 48 weeks
Study: 36911033
Drug: Early spontaneous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early spontaneous leg movements measured monthly from 1 to 4 months of age using inertial sensors
Study: 36911944
Drug: Intrathecal onasemnogene
Normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal onasemnogene abeparvovec (medium dose)
Study: 36912144
Drug: tDCS (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS (1 mA for 20 minutes) plus fifteen 45-minute sessions of naming treatment
Study: 36912144
Drug: Sham-tDCS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-tDCS plus fifteen 45-minute sessions of naming treatment
Study: 36912809
Drug: Immunotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy or chemo-immunotherapy
Study: 36913518
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication intake
Study: 36913694
Drug: Concurrent pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent pembrolizumab with AVD (doxorubicin, vinblastine, and dacarbazine)
Study: 36913959
Drug: Monthly IPTp
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly IPTp with sulfadoxine-pyrimethamine (500 mg of sulfadoxine and 25 mg of pyrimethamine for 1 day)
Study: 36913959
Drug: Monthly IPTp
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly IPTp with dihydroartemisinin-piperaquine (dosed by weight; three to five tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine once daily for 3 consecutive days)
Study: 36913959
Drug: Monthly IPTp
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly IPTp with dihydroartemisinin-piperaquine plus azithromycin (two tablets containing 500 mg once daily for 2 consecutive days)
Study: 36914185
Drug: COPDPredict with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPDPredict with rescue medication (RM)
Study: 36914185
Drug: Standard self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard self-management plans with rescue medication (RM)
Study: 36914193
Drug: Neoadjuvant arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant arterial embolisation chemotherapy (NAEC) with oxaliplatin 85 mg/m²
Study: 36914591
Drug: Dexfadrostat phosphate
Normalized name: dextroamphetamine sulfate Oral Tablet [DextroStat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfadrostat phosphate (DP13) 4 mg once daily for 8 days
Study: 36914591
Drug: Dexfadrostat phosphate
Normalized name: dextroamphetamine sulfate Oral Tablet [DextroStat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfadrostat phosphate (DP13) 8 mg once daily for 8 days
Study: 36914591
Drug: Dexfadrostat phosphate
Normalized name: dextroamphetamine sulfate Oral Tablet [DextroStat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfadrostat phosphate (DP13) 16 mg once daily for 8 days
Study: 36914652
Drug: Trotabresib (RP2D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trotabresib (RP2D of 45 mg/day 4 days on/24 days off or 30 mg/day 3 days on/11 days off)
Study: 36914828
Drug: GB1211 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB1211 5, 20, 50, 100, 200, or 400 mg (single ascending-dose)
Study: 36914828
Drug: GB1211 50
Normalized name: GB1211
DrugBank: GB1211 (DB17499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB1211 50 or 100 mg (multiple ascending-dose, twice daily for 10 days)
Study: 36914946
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin in addition to standard treatment
Study: 36914957
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin per day, initiated from 12 to 20 gestational weeks until 34 weeks of gestation
Study: 36915009
Drug: Cytokine profiles
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine profiles including IL-6, IL-10, IL-15, MDC, GRO, sCD40 L, G-CSF, and FGF-2.
Study: 36915182
Drug: Epinephrine administration
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine administration during CPR
Study: 36915199
Drug: Intranasal niclosamide
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal niclosamide
Study: 36915199
Drug: Nasal and
Normalized name: Nasal and Sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal and inhaled ciclesonide
Study: 36915199
Drug: Intravenous sotrovimab
Normalized name: sotrovimab
DrugBank: Sotrovimab (DB16355)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intravenous sotrovimab
Study: 36915287
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (increasing RUTF amount with increasing weight)
Study: 36915287
Drug: OptiMA strategy
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OptiMA strategy (decreasing RUTF dose with increasing weight and MUAC)
Study: 36915288
Drug: hsTnT level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsTnT level >14 pg/mL
Study: 36915288
Drug: hsTnT level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsTnT level ≤14 pg/mL
Study: 36915613
Drug: Molecular-instructed therapy
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular-instructed therapy recommendations
Study: 36915613
Drug: Initiated therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiated therapies based on MTB recommendations
Study: 36916707
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human acyl ghrelin (0.1 µg/kg/min)
Study: 36916707
Drug: Acyl ghrelin
Normalized name: gellan gum (low acyl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyl ghrelin antagonist D-Lys 3
Study: 36917037
Drug: Herbal drug
Normalized name: herbal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal drug combination identified by knowledge graph
Study: 36917127
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG) with care bundle including antibiotic prophylaxis, oral antibiotic prophylaxis (OAP), mechanical bowel preparation, laparoscopy, normothermia, and a wound retractor.
Study: 36917429
Drug: Risankizumab (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (180 mg or 360 mg) delivered subcutaneously via on-body injector (OBI)
Study: 36917758
Drug: Low-dose tamoxifen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tamoxifen 5 mg once daily for 3 years
Study: 36918228
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for FM
Study: 36918236
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose, 1000 mg
Study: 36918236
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate (FS), ca. 200 mg every day
Study: 36918234
Drug: Ileocolonic-delivered oral
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ileocolonic-delivered oral vitamin B
Study: 36918388
Drug: Treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effects on GFR slope
Study: 36918388
Drug: Treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effects on UACR change
Study: 36918388
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment effects on UACR change and GFR slope
Study: 36918550
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg QD on Day 1-5
Study: 36918550
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg QD with dorzagliatin 75 mg BID on Day 6-10
Study: 36918550
Drug: Dorzagliatin 75
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzagliatin 75 mg BID alone on Day 11-15
Study: 36918896
Drug: GFC-NHS-POx patch
Normalized name: (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFC-NHS-POx patch
Study: 36918896
Drug: ORC-PLGA-NHS-POx: NU-POx
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORC-PLGA-NHS-POx: NU-POx patch
Study: 36919514
Drug: Haloperidol (HAL;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (HAL; 3-mg) or fluphenazine (FLU; 3-mg)
Study: 36920397
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (150 mg oral twice daily)
Study: 36920460
Drug: 5-month nonlinear
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-month nonlinear aerobic exercise program with 3 weekly sessions
Study: 36920652
Drug: RRx-001 combined
Normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRx-001 combined with reintroduced chemotherapy (carboplatin/cisplatin and etoposide)
Study: 36920745
Drug: Remimazolam tosylate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam tosylate (high dose group, 0.08 mg/kg primary dose, 0-2.0 mg/kg/h adjustment range)
Study: 36920745
Drug: Remimazolam tosylate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam tosylate (low dose group, 0.08 mg/kg primary dose, 0-2.0 mg/kg/h adjustment range)
Study: 36920756
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (insulin pump or multiple daily injections plus continuous glucose monitor)
Study: 36921766
Drug: Sequential fractions
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential fractions (50 Gy/4f) to the lung
Study: 36921902
Drug: Lactation cookies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactation cookies (LCs) with galactagogues (56.5 g daily for 1 month)
Study: 36921902
Drug: Conventional cookies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional cookies (56.5 g daily for 1 month)
Study: 36922497
Drug: Niraparib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib monotherapy (C1)
Study: 36922593
Drug: Menin inhibitor
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menin inhibitor revumenib
Study: 36922769
Drug: Adherence-enhancing interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence-enhancing interventions performed monthly for 3 consecutive months for adolescents with VL1 > 1000 copies/ml
Study: 36922777
Drug: 90 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 µg of vitamin D supplementation